Switch theme
Sign up to access all valuation multiples
Chongqing Zhifei Biological Products Co Ltd is engaged in research and development, production and sales of vaccines and biological products.
2009
6.5K+
LTM Revenue $3.4B
LTM EBITDA $409M
$8.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chongqing Zhifei has a last 12-month revenue (LTM) of $3.4B and a last 12-month EBITDA of $409M.
In the most recent fiscal year, Chongqing Zhifei achieved revenue of $3.6B and an EBITDA of $387M.
Chongqing Zhifei expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chongqing Zhifei valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.4B | XXX | $3.6B | XXX | XXX | XXX |
| Gross Profit | $3.4B | XXX | $991M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 27% | XXX | XXX | XXX |
| EBITDA | $409M | XXX | $387M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $344M | XXX | $420M | XXX | XXX | XXX |
| EBIT Margin | 10% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $276M | XXX | $280M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chongqing Zhifei's stock price is CNY 19 (or $3).
Chongqing Zhifei has current market cap of CNY 45.8B (or $6.4B), and EV of CNY 57.9B (or $8.0B).
See Chongqing Zhifei trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.0B | $6.4B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chongqing Zhifei has market cap of $6.4B and EV of $8.0B.
Chongqing Zhifei's trades at 2.2x EV/Revenue multiple, and 20.7x EV/EBITDA.
Equity research analysts estimate Chongqing Zhifei's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chongqing Zhifei has a P/E ratio of 23.1x.
See valuation multiples for Chongqing Zhifei and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.4B | XXX | $6.4B | XXX | XXX | XXX |
| EV (current) | $8.0B | XXX | $8.0B | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 19.6x | XXX | 20.7x | XXX | XXX | XXX |
| EV/EBIT | 23.3x | XXX | 19.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.1x | XXX | 22.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChongqing Zhifei's last 12 month revenue growth is -9%
Chongqing Zhifei's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
Chongqing Zhifei's rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chongqing Zhifei's rule of X is -10% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chongqing Zhifei and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -9% | XXX | -7% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | -48% | XXX | XXX | XXX |
| Rule of 40 | 10% | XXX | 2% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -10% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chongqing Zhifei acquired XXX companies to date.
Last acquisition by Chongqing Zhifei was XXXXXXXX, XXXXX XXXXX XXXXXX . Chongqing Zhifei acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chongqing Zhifei founded? | Chongqing Zhifei was founded in 2009. |
| Where is Chongqing Zhifei headquartered? | Chongqing Zhifei is headquartered in China. |
| How many employees does Chongqing Zhifei have? | As of today, Chongqing Zhifei has 6.5K+ employees. |
| Who is the CEO of Chongqing Zhifei? | Chongqing Zhifei's CEO is Mr. Rensheng Jiang. |
| Is Chongqing Zhifei publicy listed? | Yes, Chongqing Zhifei is a public company listed on SHE. |
| What is the stock symbol of Chongqing Zhifei? | Chongqing Zhifei trades under 300122 ticker. |
| When did Chongqing Zhifei go public? | Chongqing Zhifei went public in 2010. |
| Who are competitors of Chongqing Zhifei? | Similar companies to Chongqing Zhifei include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Chongqing Zhifei? | Chongqing Zhifei's current market cap is $6.4B |
| What is the current revenue of Chongqing Zhifei? | Chongqing Zhifei's last 12 months revenue is $3.4B. |
| What is the current revenue growth of Chongqing Zhifei? | Chongqing Zhifei revenue growth (NTM/LTM) is -9%. |
| What is the current EV/Revenue multiple of Chongqing Zhifei? | Current revenue multiple of Chongqing Zhifei is 2.4x. |
| Is Chongqing Zhifei profitable? | Yes, Chongqing Zhifei is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chongqing Zhifei? | Chongqing Zhifei's last 12 months EBITDA is $409M. |
| What is Chongqing Zhifei's EBITDA margin? | Chongqing Zhifei's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Chongqing Zhifei? | Current EBITDA multiple of Chongqing Zhifei is 19.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
